Cardiomyopathy, Hypertrophic

"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Descriptor ID	D002312
MeSH Number(s)	C14.280.238.100 C14.280.484.150.070.160
Concept/Terms	Cardiomyopathy, Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathies, Hypertrophic Hypertrophic Cardiomyopathies Hypertrophic Cardiomyopathy Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathies, Hypertrophic Obstructive Hypertrophic Obstructive Cardiomyopathies Hypertrophic Obstructive Cardiomyopathy Obstructive Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathy, Hypertrophic

Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".

Diseases [C]
Cardiovascular Diseases [C14]
Heart Diseases [C14.280]
Cardiomyopathies [C14.280.238]
Cardiomyopathy, Hypertrophic [C14.280.238.100]
Heart Valve Diseases [C14.280.484]
Aortic Valve Stenosis [C14.280.484.150]
Aortic Stenosis, Subvalvular [C14.280.484.150.070]
Cardiomyopathy, Hypertrophic [C14.280.484.150.070.160]

Below are MeSH descriptors whose meaning is related to "Cardiomyopathy, Hypertrophic".

Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".

Cardiomyopathy, Hypertrophic
Cardiomyopathy, Hypertrophic, Familial

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in this website by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publications.

Bar chart showing 446 publications over 25 distinct years, with a maximum of 31 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	6	1	7
2003	8	0	8
2004	11	0	11
2005	13	1	14
2006	8	0	8
2007	16	2	18
2008	10	2	12
2009	25	1	26
2010	20	0	20
2011	19	0	19
2012	14	0	14
2013	11	0	11
2014	20	0	20
2015	25	2	27
2016	20	1	21
2017	20	0	20
2018	15	0	15
2019	22	0	22
2020	27	1	28
2021	18	0	18
2022	31	0	31
2023	17	0	17
2024	29	1	30
2025	21	0	21
2026	8	0	8

Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.

Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. 2026 Jun 23; 47(24):3120-3131.

View in: PubMed
Kramer CM, Kolm P, DiMarco JP, Desai MY, Ho CY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Schulz-Menger J, Friedrich MG, Maron MS, Appelbaum E, Link MS, Francis GS, Greenberg B, Jerosch-Herold M, Piechnik S, Mahmod M, Raman B, Jacoby DL, Baldassare LA, White JA, Chiribiri A, Helms AS, Choudhury L, Michels M, Bradlow WM, Salerno M, Heitner SB, Masri A, Prasad SK, Mohiddin SA, Plein S, Madias C, Mahrholdt H, Bucciarelli-Ducci C, Nightingale AK, Weinsaft JW, Kim HW, McCann GP, van Rossum A, Germans T, Williamson EE, Geske JB, Flett AS, Dawson D, Mongeon FP, Olivotto I, Crean AM, Woo A, Owens AT, Anderson L, Sharma S, Biagini E, Newby DE, Andre F, Berry C, Kim B, Larose E, Abraham TP, Hays AG, Sherrid MV, Gelfand EV, Nagueh SF, Rimoldi O, Camici P, Elstein E, Autore C, Watkins H, Weintraub WS, Neubauer S. Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry. JAMA. 2026 Jun 09; 335(22):1959-1969.

View in: PubMed
Sayed A, Rowin EJ, Maron MS, Maron BJ. Demographics and clinical implications of a global bibliographic profile for the hypertrophic cardiomyopathy literature over 66 years (1960-2025). Int J Cardiol. 2026 Sep 15; 459:134571.

View in: PubMed
Fath AR, Aglan A, Naidu SS, Mader MJ, Chilton RJ, Elgendy IY, Maron MS, Rowin EJ. Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data. J Am Heart Assoc. 2026 May 05; 15(9):e045994.

View in: PubMed
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS. Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. Am J Cardiol. 2026 Jul 01; 270:133-141.

View in: PubMed
Maron BJ, Ommen SR, Nishimura RA, McKenna WJ, Rakowski H, Sherrid MV, Olivotto I, Braunwald E, Maron MS. Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies. J Am Heart Assoc. 2026 Jun 16; 15(12):e047462.

View in: PubMed
Sakhnini A, Montazeri M, Chow C, Silver J, Signorile M, Chan R, Gollob MH, Runeckles K, Steve Fan CP, Rowin E, Maron M, Rakowski H, Adler A. Genotype and Family History as Risk Markers of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2026 Jun; 12(6):1247-1256.

View in: PubMed
Bjerregaard L, Maron MS, Jensen MSK, Dybro AM, Rasmussen TB, Poulsen SH, Rowin EJ. Relationship between symptom assessment and cardiopulmonary exercise testing in patients with obstructive hypertrophic cardiomyopathy. Int J Cardiol. 2026 Mar 15; 447:134147.

View in: PubMed
Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro A, Elliott P, Hegde SM, Kulac IJ, Lakdawala NK, Lewis GD, Mann A, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Maron MS. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. J Am Coll Cardiol. 2026 Mar 03; 87(8):1029-1042.

View in: PubMed
Nassif ME, Garcia-Pavia P, Masri A, Merkely B, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Lewis GD, Mann A, Maron MS, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Spertus JA. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2026 Mar 03; 87(8):1046-1058.

View in: PubMed

People

Explore

Similar Concepts

Top Journals